Genesystem Co., Ltd
Founded 2010, listed on KOSDAQ in 2021, Genesystem develops molecular diagnostic systems, biochips, test kits, and reaction reagents.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureGenesystem was established in March 2010 and listed on the KOSDAQ market in May 2021. Its main business is the development, manufacturing, and service of molecular diagnostic solutions, with product lines including molecular diagnostic systems, biochips, test kits, and reaction reagents. Consolidated revenue for 2025 was KRW 381 million, of which 45.52% came from exports, with products supplied through direct and indirect (distributor) sales domestically and abroad as well as OEM supply contracts.
Products & technology
- Molecular diagnostic systemPoint-of-care molecular diagnostics
- BiochipReagent-embedded test chip
- Test kitDiagnostic testing
- Reaction reagentDiagnostic reagent
Regulatory approvals
data.go.kr27 Korean MFDS device approvals · 2016–2025
- MFDSReal-time gene amplificator, nucleic acid2025-07-25Product approval · Class 2체외 제인 25-4668 호
- MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, molecular diagnostics2024-11-13Product approval · Class 4체외 제허 24-797 호
- MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, molecular diagnostics2024-11-13Product approval · Class 4체외 제허 24-793 호
- MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, molecular diagnostics2024-05-08Product approval · Class 4체외 제허 24-318 호
- MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, molecular diagnostics2024-05-08Product approval · Class 4체외 제허 24-317 호
- MFDSExtractor, nucleic acid2023-08-10Product approval · Class 1체외 제신 23-1226 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-31Product approval · Class 3체외 제허 23-459 호
- MFDSIVD reagents for extracting nucleic acids2022-11-07Product approval · Class 1체외 제신 22-1549 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2022-10-14Product approval · Class 3체외 제허 22-688 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2022-09-14Product approval · Class 3체외 제허 22-616 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2022-05-26Product approval · Class 3체외 제허 22-342 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2022-01-26Product approval · Class 3체외 제허 22-62 호
Show 15 more
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2022-01-26Product approval · Class 3체외 제허 22-61 호
- MFDSIVD reagents for extracting nucleic acids2021-12-29Product approval · Class 1체외 수신 21-2368 호
- MFDSExtractor, nucleic acid2021-12-22Product approval · Class 1체외 수신 21-2310 호
- MFDSIVD reagents for extracting nucleic acids2021-12-07Product approval · Class 1체외 제허 21-987 호
- MFDSIVD reagents for extracting nucleic acids2021-12-07Product approval · Class 1체외 제허 21-986 호
- MFDSReal-time gene amplificator, nucleic acid2021-10-28Product approval · Class 2체외 제인 21-4919 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-07-08Product approval · Class 3체외 제허 21-575 호
- MFDSReal-time gene amplificator, nucleic acid2021-06-04Product approval · Class 2체외 제인 21-4480 호
- MFDSIVD reagents for extracting nucleic acids2021-04-05Product approval · Class 1체외 제허 21-255 호
- MFDSIVD reagents for extracting nucleic acids2021-04-05Product approval · Class 1체외 제허 21-254 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-03-25Product approval · Class 3체외 제허 21-217 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-04-16Product approval · Class 3체외 제허 20-291 호
- MFDSReal-time gene amplificator, nucleic acid2020-01-30Product approval · Class 2체외 제인 20-4072 호
- MFDSReal-time gene amplificator, nucleic acid2016-10-04Product approval · Class 2체외 제인 16-4772 호
- MFDSTube, blood collecting, sealed, evacuatedRevoked2016-05-24Product approval · Class 1체외 제신 16-641 호
R&D and key agreements
Source: DART corporate disclosure입자기반 다중 PCR 기술(LEM-PIN) 활용 호흡기 4종 진단키트 개발 · 호흡기 질환 · 개발 중 · Developing four respiratory diagnostic test kits using particle-based multiplex PCR (LEM-PIN) technology licensed in from the Korea Institute of Science and Technology (KIST).
Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.
Founded in 1999 and listed on KOSDAQ in 2011, iNtRON Biotechnology develops bacteriophage-based new drugs via its itLysin and IMPA platforms alongside a molecular diagnostics business.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition